Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Showing 1-25 of 41 citing articles:

Conflicts over calcium and the treatment of COVID-19
Bernard J. Crespi, Joe Alcock
Evolution Medicine and Public Health (2020) Vol. 9, Iss. 1, pp. 149-156
Open Access | Times Cited: 59
Renin‐Angiotensin Aldosterone System Inhibitors and COVID‐19: A Systematic Review and Meta‐Analysis Revealing Critical Bias Across a Body of Observational Research
Jordan Loader, Frances C. Taylor, Erik Lampa, et al.
Journal of the American Heart Association (2022) Vol. 11, Iss. 11
Open Access | Times Cited: 19
Effects of Renin–Angiotensin System Inhibitors on Mortality and Disease Severity of COVID-19 Patients: A Meta-analysis of Randomized Controlled Trials
Juntao Yin, Chaoyang Wang, Xiaoyong Song, et al.
American Journal of Hypertension (2022) Vol. 35, Iss. 5, pp. 462-469
Open Access | Times Cited: 18
Late phase of COVID‐19 pandemic in General Cardiology. A position paper of the ESC Council for Cardiology Practice
Dimitrios Richter, Luigina Guasti, Friedrich Koehler, et al.
ESC Heart Failure (2021) Vol. 8, Iss. 5, pp. 3483-3494
Open Access | Times Cited: 25
The association of COVID-19 occurrence and severity with the use of angiotensin converting enzyme inhibitors or angiotensin-II receptor blockers in patients with hypertension
Mingfei Li, Ying Wang, Ndindam Ndiwane, et al.
PLoS ONE (2021) Vol. 16, Iss. 3, pp. e0248652-e0248652
Open Access | Times Cited: 23
Risk Factors Associated with COVID-19 Hospitalization and Mortality: A Large Claims-Based Analysis Among People with Type 2 Diabetes Mellitus in the United States
Kristina S. Boye, Elif Tokar Erdemir, Nathan D. Zimmerman, et al.
Diabetes Therapy (2021) Vol. 12, Iss. 8, pp. 2223-2239
Open Access | Times Cited: 23
Cardiac Manifestations in Patients with COVID-19: A Scoping Review
Sasha Peiris, Pedro Ordúñez, Donald J. DiPette, et al.
Global Heart (2022) Vol. 17, Iss. 1
Open Access | Times Cited: 17
Overreactive macrophages in SARS-CoV-2 infection: The effects of ACEI
Dominik Felkle, Katarzyna Zięba, Konrad Kaleta, et al.
International Immunopharmacology (2023) Vol. 124, pp. 110858-110858
Open Access | Times Cited: 8
Angiotensin Receptor Blockers and Angiotensin-Converting Enzyme Inhibitors in COVID-19: Meta-analysis/Meta-regression Adjusted for Confounding Factors
Terry Lee, Alessandro Cau, Matthew P. Cheng, et al.
CJC Open (2021) Vol. 3, Iss. 7, pp. 965-975
Open Access | Times Cited: 19
An umbrella review and meta‐analysis of renin–angiotensin system drugs use and COVID‐19 outcomes
Amanj Kurdi, Tanja Mueller, Natalie Weir
European Journal of Clinical Investigation (2022) Vol. 53, Iss. 2
Open Access | Times Cited: 12
Potential use of renin-angiotensin-aldosterone system inhibitors to reduce COVID-19 severity
Jorge Gonçalves, Catarina D. Santos, Paula Fresco, et al.
Revista Portuguesa de Cardiologia (2023) Vol. 42, Iss. 4, pp. 373-383
Open Access | Times Cited: 7
Cardiovascular drugs and COVID‐19 clinical outcomes: A living systematic review and meta‐analysis
Innocent G. Asiimwe, Sudeep Pushpakom, Richard M. Turner, et al.
British Journal of Clinical Pharmacology (2021) Vol. 87, Iss. 12, pp. 4534-4545
Open Access | Times Cited: 17
Interactions of Renin-Angiotensin System and COVID-19: The Importance of Daily Rhythms in ACE2, ADAM17 and TMPRSS2 Expression
Jana Zlacká, Katarína Stebelová, Michal Zeman, et al.
Physiological Research (2021), pp. S177-S194
Open Access | Times Cited: 17
ACE2 and Innate Immunity in the Regulation of SARS-CoV-2-Induced Acute Lung Injury: A Review
Lihua Qu, Chao Chen, Tong Yin, et al.
International Journal of Molecular Sciences (2021) Vol. 22, Iss. 21, pp. 11483-11483
Open Access | Times Cited: 16
Role of Serine Proteases and Host Cell Receptors Involved in Proteolytic Activation, Entry of SARS-CoV-2 and Its Current Therapeutic Options
Gashaw Dessie, Tabarak Malik
Infection and Drug Resistance (2021) Vol. Volume 14, pp. 1883-1892
Open Access | Times Cited: 15
COVID-19 in renal transplant recipients and general population: a comparative study of clinical, laboratory, and radiological features, severity, and outcome
Ali Monfared, Leila Akhondzadeh, Mahsa Mousazadeh, et al.
Virology Journal (2021) Vol. 18, Iss. 1
Open Access | Times Cited: 15
Renin–angiotensin–aldosterone system blockers and region-specific variations in COVID-19 outcomes: findings from a systematic review and meta-analysis
Upinder Kaur, Sankha Shubhra Chakrabarti, Tejas Patel
Therapeutic Advances in Drug Safety (2021) Vol. 12
Open Access | Times Cited: 12
Why antidiabetic drugs are potentially neuroprotective during the Sars-CoV-2 pandemic: The focus on astroglial UPR and calcium-binding proteins
Carlos‐Alberto Gonçalves, Patrícia Sesterheim, Krista Minéia Wartchow, et al.
Frontiers in Cellular Neuroscience (2022) Vol. 16
Open Access | Times Cited: 8
Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers Withdrawal Is Associated with Higher Mortality in Hospitalized Patients with COVID-19
Emilia Roy‐Vallejo, Aquilino Sánchez Purificación, José D. Torres‐Peña, et al.
Journal of Clinical Medicine (2021) Vol. 10, Iss. 12, pp. 2642-2642
Open Access | Times Cited: 9
Angiotensin-Converting Enzyme Inhibitor and Angiotensin Receptor Blocker Use Associated with Reduced Mortality and Other Disease Outcomes in US Veterans with COVID-19
John G. Rizk, Cachet Wenziger, Diana Tran, et al.
Drugs (2021) Vol. 82, Iss. 1, pp. 43-54
Open Access | Times Cited: 9
Update Alert 7: Risks and Impact of Angiotensin-Converting Enzyme Inhibitors or Angiotensin-Receptor Blockers on SARS-CoV-2 Infection in Adults
Katherine Mackey, Devan Kansagara, Kathryn Vela
Annals of Internal Medicine (2021) Vol. 174, Iss. 2, pp. W25-W29
Open Access | Times Cited: 9
Association of outpatient use of renin–angiotensin–aldosterone system blockers on outcomes of acute respiratory illness during the COVID-19 pandemic: a cohort study
Molly M. Jeffery, Lucas Oliveira J. e Silva, Fernanda Bellolio, et al.
BMJ Open (2022) Vol. 12, Iss. 7, pp. e060305-e060305
Open Access | Times Cited: 6
Percutaneous Coronary Intervention Associated with a Higher Risk of Hypoxemia and COVID-19 Severity
Sepideh Karkon Shayan, Elham Nasrollahi, Yaser Bahramvand, et al.
Current Medicinal Chemistry (2023) Vol. 31, Iss. 10, pp. 1265-1277
Closed Access | Times Cited: 3
Discontinuation of Antihypertensive Drug Use Compared to Continuation in COVID-19 Patients: A Systematic Review with Meta-analysis and Trial Sequential Analysis
Diego Chambergo‐Michilot, Fernando M. Runzer‐Colmenares, Pedro Segura-Saldaña
High Blood Pressure & Cardiovascular Prevention (2023) Vol. 30, Iss. 3, pp. 265-279
Open Access | Times Cited: 3
Meta-analysis of the association between angiotensin pathway inhibitors and COVID-19 severity and mortality
Malindu E. Fernando, Aaron Drovandi, Jonathan Golledge
Systematic Reviews (2021) Vol. 10, Iss. 1
Open Access | Times Cited: 8
Page 1 - Next Page

Scroll to top